Menu Search
Equities

Clover Health Investments Corp

7QD:BER

Clover Health Investments Corp

Actions
  • Price (EUR)3.19
  • Today's Change0.058 / 1.85%
  • Shares traded19.41k
  • 1 Year change+254.16%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clover Health Investments, Corp. is a physician-enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. It offers a software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.

  • Revenue in USD (TTM)1.54bn
  • Net income in USD-95.26m
  • Incorporated2021
  • Employees552.00
  • Location
    Clover Health Investments Corp3401 Mallory Lane, Suite 210, Suite 320FRANKLIN 37067United StatesUSA
  • Phone+1 (201) 432-2133
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cloverhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.